Skip to Main Content

Paper Details

Three-Year Safety Results of SAR422459 (EIAV-ABCA4) Gene Therapy in Patients With ABCA4-Associated Stargardt Disease: An Open-Label Dose-Escalation Phase I/IIa Clinical Trial, Cohorts 1-5.
Am J Ophthalmol
17
2022
Author NameAffiliation
Dongseok ChoiFrom the Casey Eye Institute, Oregon Health & Science University, P.Y.) OHSU-PSU School of Public Health
Richard G WeleberFrom the Casey Eye Institute, Oregon Health & Science University
Mark E PennesiFrom the Casey Eye Institute, Oregon Health & Science University
  • 1 - 3

Datasets